Navigation Links
REVIVE Trial Results for Avanafil Published in JSM Demonstrate Significant Improvement in Erectile Function
Date:1/17/2012

aluate the number of successful intercourse attempts at various time points post-dosing revealed that avanafil was associated with a significant treatment response as early as 15 minutes and beyond 6 hours after dosing.
  • Nearly 80% of all sexual attempts among patients in the 200mg dose group of avanafil had erections sufficient for intercourse.
  • 72% of study participants had tried at least one other ED treatment.
  • The most common side effects were headache, flushing, nasal congestion and back pain and no drug-related serious adverse events reported.
  • The completion rate in REVIVE was 85.1%  and discontinuations due to adverse events were 1.9%, 3.1%, 2.5% and 3.1%  for the 50mg, 100mg, 200mg and placebo groups, respectively.
  • About the REVIVE Study

    REVIVE (TA-301) was a randomized, double-blind, placebo-controlled, phase 3 study of avanafil in 646 men in the general population with a history of ED for at least six months; 72% of study participants had tried at least one other ED treatment. Patients underwent a four-week, non-treatment run-in period followed by 12 weeks of treatment with one of three doses of avanafil: 50mg, 100 mg and 200mg or placebo. Patients were instructed to attempt sexual intercourse 30 minutes after taking avanafil, with no restrictions on food or alcohol consumption. The primary endpoints of the study were improvement in erectile function as measured by the Sexual Encounter Profile (SEP) and improvements in the International Index of Erectile Function (IIEF) score; secondary endpoints included patient satisfaction with erections and with sexual experience. The phase 3 study was conducted under a Special Protocol Assessment with the U.S. FDA.

    About Avanafil

    Avanafil is an oral investigational drug being developed for the treatment of erectile dysfunction.  Avanafil is a highly selective phosphodiesterase type 5 (PDE5) inhibi
    '/>"/>

    SOURCE VIVUS
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. Harvest Technologies Announces Initial Enrollment in Its REVIVE-1 Trial (REtrograde Vascular Infusion of BMAC to ImproVe Heart FailurE)
    2. Secret of sandcastle construction could help revive ancient building technique, researchers say
    3. Biomerix Corporation Announces FDA Clearance and Market Launch of REVIVE(TM) for Use in Soft Tissue Repair Procedures
    4. Neuralstem President and CEO to Update Ongoing ALS and NSI-189/Major Depressive Disorder Trials at 2012 Biotech Showcase
    5. NW Bio Reaches 25 Clinical Trial Sites Open and Recruiting By the End of Q4, 2011
    6. Baxter Initiates Phase I Clinical Trial of Longer-acting Recombinant FVIII Treatment for Hemophilia A
    7. Use Biomarkers in Alzheimers Disease Clinical Trials, Says Expert Group
    8. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
    9. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
    10. US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium
    11. Post Heart Attack Recovery Not Aided By Stem Cell Injections, But Trial Demonstrates Promise
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/10/2014)... July 10, 2014 Research and Markets ... the "International Photonic Integrated Circuit (Monolithic Integration, ... 2019" report to their offering. ... concept of photonic integration traces its roots in ... promise of photonic integration went unexplored and unfulfilled ...
    (Date:7/10/2014)... of Adelaide research may help in the fight against ... detect tiny quantities of explosives with the use of ... journal Sensors and Actuators B: Chemical , the ... detect explosives in concentrations as low as 6.3 ppm ... only a few minutes. , "Traditionally explosives detection has ...
    (Date:7/10/2014)... has been extremely challenging because there are many genetic ... cause disease. Now investigators reporting in the July 3rd ... Cell describe a strategy that may help reveal ... factors or environmental exposures to affect the development of ... that may predispose individuals to schizophrenia. , The ...
    (Date:7/10/2014)... upside down forever. Nanophysics makes sure of that. Mechanics researchers ... published in Physical Review E . Knowledge that can ... seem to be able to sit still forever, and walk ... We will soon be able to buy smart new fasteners ... the fact is, sooner or later the grip is lost, ...
    Breaking Biology Technology:International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2Detecting trace amounts of explosives with light 2New strategy could uncover genes at the root of psychiatric illnesses 2Even geckos can lose their grip 2
    ... CARLOS, Calif., Jan. 5 Nektar Therapeutics,(Nasdaq: ... Robin, is,scheduled to present at the upcoming 27th Annual ... St. Francis Hotel on Tuesday,January 13, 2009 at 10:00 ... The presentation will be accessible via ...
    ... ... (PRWEB) December 17, 2008 -- Facilitating the entry of ... analyzer, now updated to effortlessly examine not only the wireless interface ... but also the interface between the device CPU and the Bluetooth ...
    ... /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Alternext ... identifies, develops and commercializes differentiated products for ... received clearance from Canadian regulatory authorities to ... for nimotuzumab, its EGFR-targeting antibody, in combination ...
    Cached Biology Technology:Newly Available To Medical Device Manufacturers - Bluetooth Testing Equipment 2Newly Available To Medical Device Manufacturers - Bluetooth Testing Equipment 3YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 2YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 3YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 4YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 5YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 6YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 7
    (Date:7/11/2014)... researchers at the National Institute of Standards and ... their work more effectively, they often prove that ... was the case recently for M. Lorna De ... the growing specialization of glycomics. Glycomics is the ... glycans that are attached to proteins and lipids ...
    (Date:7/11/2014)... from The Chinese University of Hong Kong, BGI and ... linked to salt tolerance, with implication for improving this ... published online in Nature Communications provides an ... improvement. , Soybean is an important crop for the ... have less genetic diversities than their wild counterparts. Among ...
    (Date:7/11/2014)... 3, 2014, Shenzhen, China Researchers from Salk Institute ... the first time evaluated the safety and reliability ... successfully developed a new method, TALEN-HDAdV, which could ... stem cell (hiPSC). This study published online in ... theoretical foundation for stem cell-based gene therapy. , ...
    Breaking Biology News(10 mins):BGI reports a novel gene for salt tolerance found in wild soybean 2A new genome editing method brings the possibility of gene therapies closer to reality 2
    ... JUPITER, FL, October 26, 2010 The Scripps Research Institute ... Fox Foundation to study a pair of genetic mutations that ... for Parkinson,s disease, a progressive and fatal neurodegenerative disorder. ... director for drug discovery at Scripps Florida, is the principal ...
    ... the brain, which scavenge pathogens and damaged neurons, are also ... by Duke neuroscientists. Earlier studies by Staci Bilbo, an ... rats experiencing an infection at an early age have an ... learning and memory. In a study published in ...
    ... has a companion among emerging futuristic "e-sensing" devices intended ... is a "magnetic tongue" -- a method used to ... sweet, bitter, sour, etc. A report on use of ... Journal of Agricultural and Food Chemistry . ...
    Cached Biology News:Scripps Research scientist awarded $500,000 grant to study Parkinson's disease 2Scripps Research scientist awarded $500,000 grant to study Parkinson's disease 3Source found for immune system effects on learning, memory 2Source found for immune system effects on learning, memory 3